Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Innodata Inc (INOD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Innodata Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $287.7 (market cap $39.89B), while Innodata Inc trades at $68.82 (market cap $2.21B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 18× Innodata Inc's market cap, and Innodata Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | INOD | |
|---|---|---|
Market Cap | $39.89B | $2.21B |
Sector | Health | Technology |
52-Week High | $491.22 | $121.50 |
52-Week Low | $278.09 | $34.45 |
Enterprise Value | $38.15B | $2.10B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
INOD trades at $67.80, down 1.99% amid bearish technical signals despite strong fundamental performance. The stock shows robust revenue growth with 2025 revenue of $251.66M and net income of $32.18M, supported by consistent earnings beats. Analyst consensus remains bullish with a $130 price target, though recent insider selling and technical weakness create near-term pressure.
Outlook remains positive given AI-driven growth potential and strong profitability metrics, but investors face volatility risks from high valuation multiples and competitive pressures in the AI data services space. The stock's current pullback presents a potential entry point for long-term investors believing in the AI growth story.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Innodata Inc
Innodata is a global data engineering company that provides solutions for training AI models. It helps enterprises solve complex data challenges through high-quality data annotation and digital transformation.
Read more on INOD →
